Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Inc (VRDN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 988,555
  • Shares Outstanding, K 28,464
  • Annual Sales, $ 2,960 K
  • Annual Income, $ -79,410 K
  • 60-Month Beta 0.99
  • Price/Sales 499.67
  • Price/Cash Flow N/A
  • Price/Book 3.82
Trade VRDN with:

Options Overview Details

View History
  • Implied Volatility 80.42% ( +4.49%)
  • Historical Volatility 66.85%
  • IV Percentile 41%
  • IV Rank 32.88%
  • IV High 240.78% on 08/12/22
  • IV Low 1.85% on 03/15/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 111
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 1,534
  • Open Int (30-Day) 2,074

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.72
  • Number of Estimates 7
  • High Estimate -0.50
  • Low Estimate -0.86
  • Prior Year -1.32
  • Growth Rate Est. (year over year) +45.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.95 +14.19%
on 01/09/23
39.00 -12.31%
on 01/25/23
+6.74 (+24.54%)
since 01/06/23
3-Month
18.00 +90.00%
on 11/14/22
39.00 -12.31%
on 01/25/23
+15.27 (+80.67%)
since 11/08/22
52-Week
9.47 +261.14%
on 05/09/22
39.00 -12.31%
on 01/25/23
+14.21 (+71.09%)
since 02/08/22

Most Recent Stories

More News
Wall Street Analysts Predict an 89% Upside in Viridian Therapeutics, Inc. (VRDN): Here's What You Should Know

The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

VRDN : 34.20 (-1.53%)
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

VRDN : 34.20 (-1.53%)
LVTX : 3.66 (-6.03%)
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

RANI : 5.76 (+0.17%)
VRDN : 34.20 (-1.53%)
Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is engaged as a biotechnology company, which is focused on the research and development of

VRDN : 34.20 (-1.53%)
Bed Bath & Beyond Leads Meme Stocks, But Here's Monday's Big Stock Winner

In a dour market open, here's why these stocks are on the rise.

COMP : 4.14 (-2.13%)
$DOWI : 33,949.01 (-0.61%)
$SPX : 4,117.86 (-1.11%)
$NASX : 11,910.52 (-1.68%)
BBBY : 2.61 (-13.29%)
VRDN : 34.20 (-1.53%)
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -23.26% and 63.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

VRDN : 34.20 (-1.53%)
KMDA : 4.40 (-2.22%)
Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of 18.18% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

TRVN : 1.4400 (-2.70%)
VRDN : 34.20 (-1.53%)
Cytek Biosciences, Inc. (CTKB) Q2 Earnings Surpass Estimates

Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 50% and 2.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CTKB : 13.00 (-3.49%)
VRDN : 34.20 (-1.53%)
Berkeley Lights, Inc. (BLI) Reports Q2 Loss, Misses Revenue Estimates

Berkeley Lights, Inc. (BLI) delivered earnings and revenue surprises of -26.67% and 14.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BLI : 2.11 (-6.64%)
VRDN : 34.20 (-1.53%)
Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022

WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for...

VRDN : 34.20 (-1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

See More

Key Turning Points

3rd Resistance Point 36.42
2nd Resistance Point 35.88
1st Resistance Point 35.04
Last Price 34.20
1st Support Level 33.65
2nd Support Level 33.11
3rd Support Level 32.27

See More

52-Week High 39.00
Last Price 34.20
Fibonacci 61.8% 27.72
Fibonacci 50% 24.24
Fibonacci 38.2% 20.75
52-Week Low 9.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar